PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-1.12%
Both companies show declining cash positions (-1.12% vs AGEN's -30.83%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Below half of AGEN's -11.60%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Below half of AGEN's -12.33%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Below half of AGEN's -10.66%. Michael Burry sees a potential red flag for stagnation or capital shortage.
36.86%
Similar yoy growth to AGEN's 35.47%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.96%
Less than half of AGEN's -13.45%. David Dodd sees a more disciplined short-term liability approach.
4.78%
Above 1.5x AGEN's 3.19%. Michael Burry suspects significant leverage additions. Check coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.78%
Less than half of AGEN's -10.27%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
10.65%
Less than half of AGEN's -10.55%. David Dodd sees far fewer liability expansions relative to competitor.
382.94%
Above 1.5x AGEN's 0.04%. Michael Burry suspects heavy new equity expansion or dilution.
-3.62%
Below half AGEN's 0.33%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
382.94%
Above 1.5x AGEN's 100.89%. Michael Burry suspects a significant bump in 'other' equity items vs. competitor.
-10.94%
Below half AGEN's 10.23%. Michael Burry sees potential underperformance in building shareholder capital.
-1.12%
Below half AGEN's -10.66%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
4.78%
Above 1.5x AGEN's 3.18%. Michael Burry sees a major jump. Investigate leverage rationale.
4.98%
Less than half of AGEN's 54.82%. David Dodd sees better deleveraging or stronger cash buildup than competitor.